Equinor Reportedly Scores Final Permit, Empire Wind 1 To Blast Off In 2026
Equinor received approval to build Empire Wind 1 offshore wind farm, expected to contribute to NY's goal of 9,000 MW of offshore wind power by 2035.
Major Indexes Close In The Red, Dow Falls Below 40,000 As Investors Make U-Turn On Economic Outlook
Dow Jones closes 0.1% lower; S&P 500 & Nasdaq 100 fall 0.2%; Mixed data on inflation, jobless claims and housing.
Dow Jones Hits 40,000, Chinese Tech Stocks Jump To 15-Month Highs, Bloodbath On Meme Stocks: What’s Driving Markets Thursday?
U.S. major stock indices climbed higher on Thursday morning, with the Dow Jones Industrial Average achieving a historic milestone by surpassing 40,000 points.
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with mild to moderate adverse events.
‘Big Short’ Investor Michael Burry Bets Heavy On Gold, Renewable Energy Stocks, Exits Amazon, Alphabet
Michael Burry, famous for predicting 2008 crisis, made headlines with his latest 13F filing. He shifted towards commodities & renewable energy and decreased holdings in tech giants.
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Boeing Stock Takes Off After US Aviation Bill Passes, But Possible Turbulence Ahead With Legal Uncertainties
Boeing faces regulatory changes, legal challenges, and mixed technical signals. While an aviation bill offers hope, DOJ's warning adds uncertainty.
FDA Approves Expanded Use Of Bristol Myers Squibb’s Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.
AstraZeneca’s COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.